Literature DB >> 8906227

Synthesis of type 1 (IFN gamma) and type 2 (IL-4, IL-5, and IL-10) cytokines by human eosinophils.

B Lamkhioued1, A S Gounni, D Aldebert, E Delaporte, L Prin, A Capron, M Capron.   

Abstract

Eosinophils are not only the source of cytotoxic and proinflammatory mediators but they can also generate cytokines and growth factors, including their own factors of differentiation, namely IL-3, GM-CSF, and IL-5. Synthesis of IL-5 by eosinophils was demonstrated by in situ hybridization and immunostaining in a variety of diseases, such as coeliac disease, asthma, hypereosinophilic syndrome, or skin diseases. However, IL-5 synthesis by eosinophils was not shown in Crohn's disease, whereas in other diseases, it was restricted to a subpopulation of eosinophils, suggesting some heterogeneity in cytokine-producing eosinophils. Here, we report that human eosinophils, in addition to the synthesis of IL-5, and Th2 cytokine, can synthesize IFN gamma, a Th1 cytokine, as well as IL-10 and IL-4, known to be mainly produced by Th2 cells. Double immunostaining procedures reveal the coexpression of IL-5, IL-4, and IL-10 by the same eosinophil populations, different from IFN gamma-producing eosinophils. We propose that distinct subpopulations of human eosinophils express Th2 or Th1 cytokines. These results point to the importance of cytokines derived from non T cells in the regulation of the immune response.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8906227     DOI: 10.1111/j.1749-6632.1996.tb32582.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  20 in total

Review 1.  Mechanisms of eosinophil cytokine release.

Authors:  Christianne Bandeira-Melo; Peter F Weller
Journal:  Mem Inst Oswaldo Cruz       Date:  2005-06-14       Impact factor: 2.743

2.  The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease.

Authors:  Yoshiyuki Yamada; Marc E Rothenberg; Andrew W Lee; Hiroko Saito Akei; Eric B Brandt; David A Williams; Jose A Cancelas
Journal:  Blood       Date:  2006-01-17       Impact factor: 22.113

3.  Coinfection with Borrelia burgdorferi and the agent of human granulocytic ehrlichiosis alters murine immune responses, pathogen burden, and severity of Lyme arthritis.

Authors:  V Thomas; J Anguita; S W Barthold; E Fikrig
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

Review 4.  [Ocular allergies].

Authors:  E M Messmer
Journal:  Ophthalmologe       Date:  2005-05       Impact factor: 1.059

5.  Posttreatment Reactions After Single-Dose Diethylcarbamazine or Ivermectin in Subjects With Loa loa Infection.

Authors:  Jesica A Herrick; Fanny Legrand; Raceline Gounoue; Godwin Nchinda; Céline Montavon; Jean Bopda; Steve Mbickmen Tchana; Bienvenu Etogo Ondigui; Konrad Nguluwe; Michael P Fay; Michelle Makiya; Simon Metenou; Thomas B Nutman; Joseph Kamgno; Amy D Klion
Journal:  Clin Infect Dis       Date:  2017-04-15       Impact factor: 9.079

6.  Interleukin-4 receptor alpha chain and STAT6 signaling inhibit gamma interferon but not Th2 cytokine expression within schistosome granulomas.

Authors:  Ahmed Metwali; Arthur Blum; David E Elliott; Joel V Weinstock
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

7.  Novel transglutaminase inhibitors reverse the inflammation of allergic conjunctivitis.

Authors:  Joonhong Sohn; Tae-Im Kim; Young-Hee Yoon; Joo-Yong Kim; Soo-Youl Kim
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

Review 8.  Eosinophils in the pathogenesis of allergic airways disease.

Authors:  S G Trivedi; C M Lloyd
Journal:  Cell Mol Life Sci       Date:  2007-05       Impact factor: 9.261

9.  Eosinophils and oral squamous cell carcinoma: a short review.

Authors:  C P Martinelli-Kläy; B R R N Mendis; T Lombardi
Journal:  J Oncol       Date:  2009-12-16       Impact factor: 4.375

Review 10.  Chronic inflammation and asthma.

Authors:  Jenna R Murdoch; Clare M Lloyd
Journal:  Mutat Res       Date:  2009-09-19       Impact factor: 2.433

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.